Gonadorelin
also known as GnRH, LHRH, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone
Synthetic decapeptide identical to endogenous gonadotropin-releasing hormone. Pulsatile administration restores physiological LH/FSH secretion in hypothalamic hypogonadism by mimicking native GnRH pulsatility. Single-dose administration used diagnostically to assess pituitary gonadotrope responsiveness. Continuous exposure paradoxically downregulates GnRH receptors, forming the basis for GnRH agonist desensitization protocols.
At a glance
IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)
Primary target — GnRH receptors on anterior pituitary gonadotropes.
Pathway — GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesis [sharma-2026].
Downstream effect — Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesis [robin-2026][sharma-2026].
Origin — Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH.
Feedback intact — Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors.
| Parameter | Value |
|---|---|
| Diagnostic test (pituitary function) | 100 mcg IV or SQ bolusMeasure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline. |
| Therapeutic (hypothalamic hypogonadism) | 5–20 mcg IV bolus every 90–120 minutesRequires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility. [robin-2026] |
| Pulsatile interval | 90 minutes (females) · 120 minutes (males)Mimics physiological GnRH pulse frequency. |
| Route | IV preferred (therapeutic) · SQ acceptable (diagnostic) |
| Duration | Continuous until pregnancy achieved or fertility goals met3–6 month courses typical for ovulation induction. |
| Evidence basis | RCT / Expert consensus |
| Half-life | 2–4 minutes (plasma)Necessitates frequent pulsatile administration. |
| Alternative protocols | Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
No direct lipolytic mechanisms. Primary indication is reproductive axis restoration.
| Outcome | Finding |
|---|---|
| Fat loss mechanism | None — gonadorelin acts exclusively on reproductive axis |
| Indirect metabolic effects | Restoration of sex hormones may normalize body composition in hypogonadal statesEffect mediated by downstream testosterone/estradiol, not GnRH itself. |
- — Pregnancy (except therapeutic infertility protocols)
- — Hypersensitivity to gonadorelin or excipients
- — Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation
- — Ovarian cysts or PCOS (monitor for OHSS)
- — Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)
- 01Diagnostic protocol
Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.
- 02Therapeutic pump setup (pulsatile)
Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.
- 03Reconstitution
Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.
- 04Monitoring
For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.
- 05Timing
Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.
Sources
of 61 rendered claims carry a resolvable citation.
- [morris-2026]Morris 2026 — Robust serotonin activation of the kisspeptin GnRH pulse generator in male and female mice.
journal, 2026 - [robin-2026]Robin 2026 — Management of infertility in women with hypothalamic hypogonadotropic hypogonadism: an expert opinion.
journal, 2026 - [sharma-2026]Sharma 2026 — Delayed Puberty.
journal, 2026 - [tadesse-2026]Tadesse 2026 — Clomiphene citrate in the management of anovulation: a review of mechanisms, outcomes, and clinical challenges.
journal, 2026 - [wittner-2026]Wittner 2026 — Novel KISS1 Gene Mutation Leading to Male Hypogonadotropic Hypogonadism.
journal, 2026